Close Menu

NEW YORK (GenomeWeb News) – Agilent Technologies announced today that it will split into two publicly-traded companies — one focused on its life science and diagnostics business and the other on its electronic measurement business.

The life sciences and diagnostics business, which also includes applied markets, has annual revenues of around $3.9 billion. It will retain the Agilent name, and current Agilent CEO William Sullivan will retain the same role and also serve as president of the company. CFO Didier Hirsch also will continue as CFO.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.

Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.

Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.

In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.